ã²ãã ç·šéã®å¯èœæ§ã®è§£æ:åžå Žååãæšé²èŠå ã驿°çãªãœãªã¥ãŒã·ã§ã³
ã²ãã ç·šéãšã¯äœã§ããããã®å©ç¹ã¯äœã§ããïŒ
ã²ãã ç·šéãšã¯ãçç©ã®DNAé
åãæšçãšãã倿Žãè¡ãããã»ã¹ã®ããšã§ãã ã²ãã ç·šéã®ç®çã¯ãéºäŒåã®æ¬ é¥ãä¿®æ£ããäœç©ã®åç©«éãæ¹åããéºäŒç
ã«å¯Ÿããæ°ããæ²»çæ³ãéçºããããšã§ãã ã²ãã ç·šéã®å©ç¹ã¯æ¬¡ã®ãšããã§ã:
ç·šéããã»ã¹ã®æ£ç¢ºãªå¶åŸ¡
ç¹å®ã®éºäŒåã«å¯ŸããŠæšçåã®å€æŽãè¡ãèœå
éºäŒæ§çŸæ£ãæ²»çããå¯èœæ§
äœç©ã®åç©«éã®åäžãšå®³è«ãç
æ°ã«å¯Ÿããæµæåã®åäž
殺è«å€ãšé€èå€ã®å¿
èŠæ§ã®æžå°
ã²ãã ç·šéåžå Žã¯ä»åŸæ°å¹ŽéãéºäŒåæ²»çãšäœç©æ¹è¯ã®éèŠå¢å ã«æ¯ãããã倧ããæé·ãããã®ãšäºæ³ãããã åžå Žã¯ãæ°ããç·šéããŒã«ãæè¡ã®éçºãªã©ãæè¡ã®é²æ©ã«ãã£ãŠçœåŒããããšæåŸ ãããŠããŸãã ã²ãã ç·šéãåžå Žã«åãŒã圱é¿ã倧ãããéºäŒçŸæ£ã«å¯Ÿããæ°ããæ²»çå€ã®éçºãå¯èœã«ãªããäœç©ã®åç©«éãšå質ãåäžããã ããã
ã²ãã ç·šéåžå Žåæå ¥é
ã²ãã ç·šéåžå Žåæã¯ã1次ç ç©¶ãš2次ç ç©¶ã®çµã¿åããã䜿çšããŠè¡ãããã äžæ¬¡ç ç©¶ã§ã¯ãç ç©¶è ãç§åŠè ãèšåºå»ãªã©ã®æ¥çå°éå®¶ãšã®ã€ã³ã¿ãã¥ãŒãè¡ããåžå Žã®çŸç¶ãšä»åŸã®ååã«ã€ããŠã®æŽå¯ãåŸãããšãå«ãŸããŠããŸããã 2次ç ç©¶ã¯åŠè¡è«æãç£æ¥å ±åæžããã¥ãŒã¹èšäºãªã©åºçãããæç®ãåæããåžå ŽèŠæš¡ãæé·çãç«¶äºç°å¢ãªã©ã«é¢ããè³æãåéããããšãå«ãã
ãŸããåžå ŽèŠæš¡ãç«¶äºååæãåŸååæãªã©ãããŸããŸãªåæææ³ãæ¡çšããã 䜿çšãããããŒã¿ãœãŒã¹ã«ã¯ãæ¥çã¬ããŒããåŠè¡è«æãæ¿åºçµ±èšãå«ãŸããŠããŸããã åæã¯ããã ã¢ããæ¹åŒã§è¡ãããåå¥äŒæ¥ãšåžå Žã»ã°ã¡ã³ãã®åçãéèšããŠåžå ŽèŠæš¡ãæšå®ããã
åæçµæã«ãããšãã²ãã ç·šéåžå Žã¯éºäŒåæ²»çãšäœç©æ¹åã®éèŠå¢å ã«æ¯ããããäºæ³æéäžã«18.10%ã®CAGRã§æé·ãããã®ãšäºæ³ãããã åžå Žã¯ãæ°ããç·šéããŒã«ãæè¡ã®éçºãç ç©¶éçºãžã®æè³ã®å¢å ãªã©ãæè¡ã®é²æ©ã«ãã£ãŠçœåŒããããšæåŸ ãããŠããŸãã
ã¬ããŒãã®ãµã³ãã«ãååŸãã: |REPORT_SAMPLE_URL|
ã²ãã ç·šéåžå Žã®åžå Žåå
No
ã²ãã ç·šéåžå Žã¯ã以äžãå«ãããã€ãã®æå
端ã®ãã¬ã³ãã«ãã£ãŠåœ¢æãããŠããŸã:
æ°ç»å Žã®ãã¯ãããžãŒ: CRISPR-Cas9ããã®ä»ã®éºäŒåç·šéããŒã«ã®é²æ©ã«ãããããæ£ç¢ºã§å¹ççãªç·šéãå¯èœã«ãªããéºäŒåæ²»çãäœç©æ¹è¯ã®é©æ°ãæšé²ããŠããŸãã
æ¶è²»è
ã®å¥œã¿: éºäŒåçŸæ£ã«å¯Ÿããèªèãé«ãŸããå人ãªãŒããŒã¡ãŒãåå»åŠã«å¯ŸããéèŠãå¢å ããã²ãã ç·šéæè¡ã®æ¡æãçœåŒããŠããã
æ¥çã®æ··ä¹±: æ°èŠåå
¥è
ãšã¹ã¿ãŒãã¢ããã¯äŒçµ±çãªæ¥çãã¬ãŒã€ãŒãæ··ä¹±ãããæ°ãããã¯ãããžãŒãšããžãã¹ã¢ãã«ãåžå Žã«ãããããŠããã
éºäŒåæ²»ç: éç¶èµ€è¡çè²§è¡ãçãžã¹ãããã£ãŒã®ãããªéºäŒåçŸæ£ãæ²»çããããã®éºäŒåæ²»çãžã®é¢å¿ãé«ãŸã£ãŠããã
äœç©æ¹å:åç©«éãèç
æ§ãæ 逿åãæ¹åããéºäŒåçµã¿æãäœç©ã®éèŠã®å¢å ã
åæçç©åŠ: æ°ããåéãšããŠã®åæçç©åŠã®åºçŸã«ãããæ°ããçç©åŠã·ã¹ãã ã®èšèšãšæ§ç¯ãå¯èœã«ãªãã
ãã®ãããªåŸåãåå°ã«éºäŒåç·šéæè¡ã®æ¡æãå¢ããéºäŒåæ²»çãšäœç©æ¹åã«å¯ŸããéèŠãå¢å ãããªã©ãã²ãã ç·šéåžå Žã倧ããæé·ãããã®ãšæåŸ ãããã 2025幎ãŸã§ã«åžå Žã¯105åãã«ã«éããCAGR18.10%ã®æé·ãèŠèŸŒãŸããŠããã
補åã¿ã€ãã®èгç¹ãããã²ãã ç·šéåžå Žã¯æ¬¡ã®ããã«ã»ã°ã¡ã³ãåãããŠããŸã:
ã²ãã ç·šéãšã¯ãçç©ã®DNAé åãæ£ç¢ºã«å€åãããéçšãããã ã²ãã ç·šéã«ã¯ãCRISPR (Clustered Regularly Interspaceed Short Palindromic Repeats)ãTALEN (Transcription Activator-like Effector Nuclease)ãZFN (Zinc Finger Nuclease) ã® 3 ã€ã®äž»èŠãªã¿ã€ãããããŸãã CRISPRã¯ãé µçŽ ãæšçéšäœã«èªå°ããããã«å°ããªRNAååã䜿çšããæãäžè¬çã§å¹ççãªæ¹æ³ã§ãã TALENãšZFNã¯ãç¹å®ã®DNAé åãèªèããããã«ãšã³ãžãã¢ãªã³ã°ãããã¿ã³ãã¯è³ªã䜿çšããŸãã ãããã®æè¡ã¯ãã²ãã ç·šéåžå Žã®æé·ãçœåŒããéºäŒåã®ç²Ÿå¯ãªç·šéãå¯èœã«ãªããçåœå·¥åŠã蟲æ¥ãå»åŠãªã©å€æ§ãªå¿çšåéã§ã²ãã ç·šéã®éèŠãåºæ¿ãããªã©ãåéã«é©åœããããããã
補åã¢ããªã±ãŒã·ã§ã³ã«é¢ããŠã¯ãã²ãã ç·šéåžå Žã¯æ¬¡ã®ããã«çްååãããŠããŸã:
ã²ãã ç·šéã«ã¯çŽ°èæ ªå·¥åŠãåç©éºäŒå·¥åŠãæ€ç©éºäŒå·¥åŠãªã©å€æ§ãªå¿çšåéãããã çŽ°èæ ªå·¥åŠã§ã¯ãã²ãã ç·šéãå©çšããŠãçŸç ã«å¯Ÿããèæ§ãçç£æ§ã®åäžãªã©ãæãŸããç¹æ§ãçç©å·¥åŠãå»åŠã«äœ¿ãããçŽ°èæ ªã«å°å ¥ããã åç©éºäŒå·¥åŠã§ã¯ãã²ãã ç·šéãå©çšããŠãå®¶çã®çŸç èæ§ãæé·çã®åäžãªã©ã蟲æ¥çç¹æ§ãæ¹åããã æ€ç©éºäŒå·¥åŠã§ã¯ãã²ãã ç·šéã䜿çšããŠãäœç©ã®åéãèç æ§ãæ é€åãåäžãããŸãã åçã®é¢ã§æãæ¥éã«æé·ããŠããå¿çšåéã¯ãéºäŒåçµã¿æãäœç©ã®éèŠã®å¢å ã«ãã£ãŠæšé²ãããæ€ç©éºäŒå·¥åŠã§ãã
ã²ãã ç·šéåžå Žã®å°ççåºãããšåžå Žã®ãã€ããã¯ã¹
ã²ãã ç·šéåžå Žã¯ããã€ãªæè¡ã®ç ç©¶éçºã®å¢å ãéºäŒåçµã¿æãäœç©ã®éèŠã®å¢å ãéºäŒåæ²»çã®é²æ©ãªã©ãçœåŒããŠããã åç±³ã¯ãžã§ã³ã¹ã¯ãªããããã©ã€ãºã³ãã£ã¹ã«ããªãŒã°ã«ãŒãããµãŒã¢ãã£ãã·ã£ãŒãµã€ãšã³ãã£ãã£ãã¯ãªã©ã®äž»èŠäŒæ¥ã®ååšã«ãã£ãŠæšé²ãããæå€§ã®åžå Žã§ãã ãšãŒãããã¯2çªç®ã«å€§ããªåžå Žã§ããããã³ã¶ãã¡ã«ã¯KGaAã®ãããªäŒæ¥ã匷ãã ã¢ãžã¢å€ªå¹³æŽå°åã¯ãäžåœãã€ã³ãã®ãããªåœã ã§ãã€ãªãã¯ãããžãŒãžã®æè³ãå¢å ããéºäŒåçµã¿æãäœç©ã®éèŠãå¢å ããŠããããšã«ãã£ãŠãæãæ¥éã«æé·ããŠããåžå Žã§ãã äžåç±³ãšäžæ±Â·ã¢ããªã«ã¯æ°èåžå Žã§ããããã€ãªãã¯ãããžãŒãžã®æè³å¢å ãšéºäŒåç ç©¶ãä¿é²ããããã®æ¿åºã®ã€ãã·ã¢ããã«ãã£ãŠæé·ã®æ©äŒãããããããŠããã äž»èŠäŒæ¥ã¯ãåžå Žã·ã§ã¢ãæ¡å€§ããããã®æŠç¥çããŒãããŒã·ãããã³ã©ãã¬ãŒã·ã§ã³ã補åã®çºå£²ã«çŠç¹ãåœãŠãŠããŸãã æé·èŠå ãšããŠã¯ãéºäŒåç·šéæè¡ã®æ¡çšã®å¢å ãéºäŒåæ²»çã®éèŠã®å¢å ãéºäŒåç·šéããŒã«ãšæè¡ã®é²æ©ãªã©ãæããããã
ã²ãã ç·šéåžå Ž:ç«¶äºåã®ããã€ã³ããªãžã§ã³ã¹
Genscript: Genscriptã¯ãã¢ãžã¢å€ªå¹³æŽå°åã§åŒ·åãªååšæãæã€å€§æéºäŒåç·šéäŒç€Ÿã§ãã CRISPR-Cas9ãTALENãªã©ãéºäŒåç·šéããŒã«ããµãŒãã¹ã®å€æ§ãªããŒããã©ãªãªãä¿æããŠããã Genscriptã¯ããã€ãªå»è¬åã¢ããªã±ãŒã·ã§ã³ã®ããã®éºäŒåæ²»çãšéºäŒåç·šéã«çŠç¹ãåœãŠããªã©ã驿°ã®åŒ·åãªå®çžŸãæã£ãŠããŸãã
Horizon Discovery Group: Horizon Discovery Groupã¯ãéºäŒåç·šéããã³éºäŒåç·šéããŒã«ãå°éãšããè±åœã«æ ç¹ã眮ãäŒæ¥ã§ãã ãšãŒããããšåç±³ã§åŒ·ãååšæãæã£ãŠããããã€ãªå»è¬åçšéã®éºäŒåæ²»çãšéºäŒåç·šéã«éç¹ã眮ããŠããã
Lonza: Lonzaã¯ã¹ã€ã¹ã«æ ç¹ã眮ãäŒæ¥ã§ãéºäŒåç·šéãå«ãããŸããŸãªãã€ãªå»è¬åãµãŒãã¹ãæäŸããŠããŸãã ãšãŒããããšåç±³ã§åŒ·ãååšæãæã£ãŠããããã€ãªå»è¬åçšéã®éºäŒåæ²»çãšéºäŒåç·šéã«éç¹ã眮ããŠããã
Merck KGaA: Merck KGaAã¯ãéºäŒåç·šéãå«ãæ§ã
ãªãã€ãªå»è¬åãµãŒãã¹ãæäŸãããã€ãã«æ ç¹ã眮ãäŒæ¥ã§ãã ãšãŒããããšåç±³ã§åŒ·ãååšæãæã£ãŠããããã€ãªå»è¬åçšéã®éºäŒåæ²»çãšéºäŒåç·šéã«éç¹ã眮ããŠããã
ãµã³ã¬ã¢ã»ã©ããŒ: Sangamo Therapeuticsã¯ãéºäŒåç·šéãšéºäŒåæ²»çãå°éãšããç±³åœã«æ¬ç€Ÿã眮ãäŒæ¥ã§ãã åžå°éºäŒçŸæ£ã®éºäŒåæ²»çã«éç¹ã眮ããªã©ã驿°ã®å®çžŸã匷ãã
ãµãŒã¢Â·ãã£ãã·ã£ãŒÂ·ãµã€ãšã³ã¹: Thermo Fisher Scientificã¯ãéºäŒåç·šéããŒã«ãå«ãããŸããŸãªãã€ãªãã¯ãããžãŒè£œåãšãµãŒãã¹ãæäŸããç±³åœã«æ ç¹ã眮ãäŒæ¥ã§ãã åç±³ãšãšãŒãããã§åŒ·ãååšæãæã£ãŠããããã€ãªå»è¬åçšéã®éºäŒåæ²»çãšéºäŒåç·šéã«éç¹ã眮ããŠããã
販売åç:
Genscript: 1åãã«ïŒ2020幎ïŒ
Horizon Discoveryã°ã«ãŒã:5,000äžãã«ïŒ2020幎ïŒ
ãã³ã¶:25åãã«ïŒ2020幎ïŒ
Merck KGaA: 150åãã«ïŒ2020幎ïŒ
Sangamo Therapeutics: 5,000äžãã«ïŒ2020幎ïŒ
ãµãŒã¢ãã£ãã·ã£ãŒÂ·ãµã€ãšã³ãã£ãã£ãã¯:250åãã«ïŒ2020幎ïŒ
 Â
ã²ãã ç·šéåžå Žã®æé·èŠéããšäºæž¬
ã²ãã ç·šéåžå Žã¯ãäºæ³æéäžã«å¹Žå¹³å15.6%ã®å€§å¹
ãªè€åæé·ç(CAGR)ã瀺ããã®ãšäºæ³ãããã ãã€ãªã蟲æ¥ãå»è¬ãªã©å€æ§ãªå¿çšåéã§éºäŒåç·šéæè¡ã®æ¡æãå¢ããåžå Žæé·ãçœåŒããŠããã 驿°çãªæé·ååãšããŠã¯ãéºäŒåç·šéããŒã«ãšæè¡ã®é²æ©ãéºäŒåæ²»çã®éèŠã®å¢å ããã€ãªãã¯ãããžãŒç ç©¶ãžã®æè³ã®å¢å ãªã©ãæããããã
æé·ã®èŠéããé«ãããããäŒæ¥ã¯æ¬¡ã®ãããªé©æ°çãªå°å
¥æŠç¥ãæ¡çšããŠããŸã:
æŠç¥çããŒãããŒã·ãããšã³ã©ãã¬ãŒã·ã§ã³ã«ãããåžå Žãžã®é²åºãšå°éç¥èãæ¡å€§
éºäŒåç·šéæè¡ã®æ¹åã®ããã®ç ç©¶éçºãžã®æè³
äœç©æ¹è¯ã®ããã®éºäŒåç·šéãçŸç
æ²»çãªã©ãæ°ããªåžå Žãžã®æ¡å€§
CRISPR-Cas9ãTALENãªã©ã®æ°ããéºäŒåç·šéããŒã«ãæè¡ã®éçº
éºäŒåæ²»çã®ããã®éºäŒåç·šéãšãã€ãªå»è¬åã¢ããªã±ãŒã·ã§ã³ã®ããã®éºäŒåç·šéãžã®é¢å¿ã®é«ãŸã
æé·ã®å¯èœæ§ãé«ãããã¬ã³ãã«ã¯ã次ã®ãã®ããããŸã:
ãã€ãªå»è¬åã¢ããªã±ãŒã·ã§ã³ã®ããã®éºäŒåæ²»çãšéºäŒåç·šéã®éèŠã®å¢å
ãã€ãªãã¯ãããžãŒç ç©¶éçºãžã®æè³ã®å¢å
éºäŒåç·šéããŒã«ãšæè¡ã®é²æ©
蟲æ¥ããã³äœç©æ¹è¯ã«ãããéºäŒåç·šéã®æ¡çšã®æ¡å€§
åžå°éºäŒçŸæ£ãããŒãœãã©ã€ãºãããå»åŠã®ããã®éºäŒåç·šéãžã®é¢å¿ãé«ãŸã£ãŠããã
ã²ãã ç·šéåžå Žã®äž»ãªè§Šåªãšé害
ã²ãã ç·šéåžå Žã®æé·ãä¿é²ããäž»ãªèŠå ãšããŠã¯ããã€ãªãã¯ãããžãŒã蟲æ¥ãå»è¬åã®æ¡çšã®å¢å ãéºäŒåç·šéããŒã«ãšæè¡ã®é²æ©ãéºäŒåæ²»çã®éèŠã®å¢å ãªã©ããããŸãã éå£ãšèª²é¡ãå
æããããã®é©æ°çãªãœãªã¥ãŒã·ã§ã³ã«ã¯ãæŠç¥çããŒãããŒã·ãããã³ã©ãã¬ãŒã·ã§ã³ãç ç©¶éçºãžã®æè³ãå«ãŸããŸãã ãŸããäŒæ¥ã¯éºäŒåç·šéã®å¹çæ§ãç¹ç°æ§ãæ¡åŒµæ§ãæ¹åããCRISPR-Cas9ãTALENãªã©æ°ããéºäŒåç·šéããŒã«ãšæè¡éçºã«åãå
¥ããŠããã ãããã®ã€ãããŒã·ã§ã³ã¯ãæšçå€å¹æãéºäŒåç·šéå¹çãèŠå¶äžã®ããŒãã«ãªã©ã®èª²é¡ãå
æããã®ã«åœ¹ç«ã¡ãåžå Žã®æé·ãšæ¡çšãä¿é²ããŠããŸãã
 Â
ãã®ã¬ããŒãã®è³Œå
¥: |REPORT_PURCHASE_URL|